Business Description
Wuhan YZY Biopharma Co Ltd
ISIN : CNE1000063C4
Share Class Description:
HKSE:02496: Ordinary Shares - Class HTotal Employee Number:
106Compare
Compare
Traded in other countries / regions
02496.Hong Kong IPO Date
2023-09-25Description
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | -0.3 | |||||
Debt-to-Equity | -2.41 | |||||
Debt-to-EBITDA | -1.64 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.65 | |||||
Beneish M-Score | -2.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 25.5 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 50.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.02 | |||||
9-Day RSI | 1.89 | |||||
14-Day RSI | 8.87 | |||||
3-1 Month Momentum % | -17.01 | |||||
6-1 Month Momentum % | -49.04 | |||||
12-1 Month Momentum % | -32.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.66 | |||||
Quick Ratio | 0.64 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 24.07 | |||||
Days Sales Outstanding | 120.71 | |||||
Days Payable | 31.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -3.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 16.03 | |||||
Operating Margin % | -120.31 | |||||
Net Margin % | -126.55 | |||||
EBITDA Margin % | -117.35 | |||||
FCF Margin % | -33.99 | |||||
OCF Margin % | -32.65 | |||||
ROA % | -37.61 | |||||
ROIC % | -34.47 | |||||
3-Year ROIIC % | 369.46 | |||||
ROC (Joel Greenblatt) % | -183.98 | |||||
ROCE % | -295.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.74 | |||||
EV-to-EBIT | -8.54 | |||||
EV-to-EBITDA | -8.67 | |||||
EV-to-Revenue | 10.18 | |||||
EV-to-FCF | -29.94 | |||||
Earnings Yield (Greenblatt) % | -11.71 | |||||
FCF Yield % | -3.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Wuhan YZY Biopharma Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 73.426 | ||
| EPS (TTM) (HK$) | -0.483 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 58.77 | ||
| 14-Day RSI | 8.87 | ||
| 14-Day ATR (HK$) | 0.023794 | ||
| 20-Day SMA (HK$) | 3.7835 | ||
| 12-1 Month Momentum % | -32.2 | ||
| 52-Week Range (HK$) | 3.69 - 8.4 | ||
| Shares Outstanding (Mil) | 200.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Wuhan YZY Biopharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Wuhan YZY Biopharma Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Wuhan YZY Biopharma Co Ltd Frequently Asked Questions
What is Wuhan YZY Biopharma Co Ltd(HKSE:02496)'s stock price today?
The current price of HKSE:02496 is HK$3.69. The 52 week high of HKSE:02496 is HK$8.40 and 52 week low is HK$3.69.
When is next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496)?
The next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496) is .
Does Wuhan YZY Biopharma Co Ltd(HKSE:02496) pay dividends? If so, how much?
Wuhan YZY Biopharma Co Ltd(HKSE:02496) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Wuhan YZY Biopharma Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers